ORLANDO, Fla.--(BUSINESS WIRE)--The combination of Imprime PGG®, Erbitux® (cetuximab) and Camptosar® (irinotecan) nearly doubled the overall response rate of second- and third-line metastatic colorectal cancer patients compared with the standard of care of cetuximab and irinotecan alone, according to data released today at the American Society of Clinical Oncology (ASCO) annual meeting.
